Vischer acted as legal counsel to Afinum in its investment in Hofstetter PCB, the European provider of printed circuit boards plating and special final finishing services. Together with its prior investment in GS Swiss, Afinum
Tags :Vischer
Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro Ocampo’s laboratory at the University of Lausanne, has raised EUR 10 million from Prima Materia, an investment
Luciole Medical, a Swiss medical technology company specialized in brain monitoring, acquires Spiegelberg & Co., an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital. Spiegelberg has
RELIEF THERAPEUTICS Holding has entered into has entered into a definitive agreement for the sale and purchase in a private placement of 1.5m Relief shares and warrants to purchase up to 1.5m Relief shares. The
Oculis Holding, a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share,
As we have informed here, US private equity investor Battery Ventures has acquired Swiss-based SaaS startup Avrios International. Avrios offers a cloud-based fleet management platform, used by more than a thousand customers with around 120,000 vehicles.
Innovad, a provider of animal nutrition and health solutions, has acquired its Swiss competitor Herbonis and its subsidiaries in Switzerland, France and including Wyreside in the UK. The acquisition aims to strengthen Innovad’s portfolio
As we have informed here, Suixx sold the db electronic Group to NCAB Group, which is listed on Nasdaq Stockholm. The db electronic Group is active in the development, production, distribution and trading of printed
A group of investors advised by Munich-based Rigeto Unternehmerkapital has acquired prevention-center as an add-on to the Matignon Group. Prevention-center is a leading Swiss provider of cosmetic, medical and aesthetic services in the field of
Mosanna Therapeutics, a Basel-based biotechnology company developing the highly differentiated small molecule MOS118 for the treatment of metabolic obstructive sleep apnea, has closed an extension of the Seed Financing Round with the investors Supermoon Capital,